Latest Conference Articles

The triplet regimen of elotuzumab plus pomalidomide and dexamethasone led to a 46% reduction in the risk of death compared with pomalidomide/dexamethasone alone in patients with relapsed/refractory multiple myeloma, according to updated findings of the phase II ELOQUENT-3 trial.

Simon Rule, MD, PhD, Plymouth University Medical School, discusses results of the phase III MabCute study evaluating subcutaneous rituximab as maintenance after standard subcutaneous rituximab induction and maintenance in patients who have relapsed or refractory indolent non-Hodgkin lymphoma.

Ajai Chari, MD, Icahn School of Medicine at Mount Sinai, discusses INSIGHT MM (NCT02761187), the largest global, prospective, non-interventional, observational study on multiple myeloma to date.

The efficacy of larotrectinib is supported in distinct patient populations with TRK fusion cancer—specifically pediatric patients and adult or pediatric patients with brain metastases or primary central nervous system tumors.

Neratinib combined with capecitabine reduced the risk of disease progression or death by 24% compared with lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer who received at least 2 prior lines of HER2-targeted therapy.

Adding the Akt inhibitor capivasertib to fulvestrant led to a more than doubling of progression-free survival compared with fulvestrant alone in patients with endocrine-resistant estrogen receptor-positive advanced breast cancer.

Margetuximab, a novel Fc-engineered HER2-targeted antibody, improved progression-free survival compared with trastuzumab in patients with pretreated HER2-positive metastatic breast cancer in the open-label phase III SOPHIA clinical trial.

Simultaneous targeting of Bruton’s tyrosine kinase and the CD20 antigen led to overall responses in more than 90% of patients with chronic lymphocytic leukemia, including untreated and relapsed/refractory disease.

Hope S. Rugo, MD, director, Breast Oncology and Clinical Trials Education, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the phase III SOPHIA trial of margetuximab plus chemotherapy versus trastuzumab (Herceptin) plus capecitabine in patients with HER2-positive metastatic breast cancer after prior anti–HER2-targeted therapies.

Caroline Robert, MD, PhD, head of the Dermatology Unit in Gustave Roussy Cancer Center, Villejuif-Paris, France, discusses results of a 5-year analysis evaluating the long-term effects of dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with BRAF V600–mutant unresectable or metastatic melanoma.

The PARP inhibitor olaparib reduced the risk of disease progression or death by 38% versus chemotherapy in patients with platinum-sensitive, relapsed, germline BRCA1/2-mutated ovarian cancer who received at least 2 prior lines of chemotherapy.

The addition of venetoclax to obinutuzumab reduced the risk for disease worsening or death by 65% compared with obinutuzumab plus chlorambucil in patients with previously untreated chronic lymphocytic leukemia.

A chemotherapy-free doublet for platinum-sensitive recurrent ovarian cancer more than doubled progression-free survival as compared with single-agent PARP inhibitor.

Two new therapies are showing encouraging findings for patients with NSCLC with either RET rearranged or EGFR exon 20 insertions, raising hope that 2 hard-to-target driver alterations may soon have an associated targeted treatment.

Paul G. Richardson, MD, clinical program leader and director of clinical research at the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, discussed the phase III ICARIA-MM trial, which looked at the triplet regimen of isatuximab, pomalidomide (Pomalyst), and dexamethasone in patients with relapsed/refractory multiple myeloma.

The investigational KRASG12C inhibitor AMG 510 achieved a 50% response rate in patients with KRASG12C-positive advanced non–small cell lung cancer, according to results from a phase I study presented at the 2019 ASCO Annual Meeting.

Daniel P. Petrylak, MD, professor of medicine and urology at Yale Cancer Center, 2017 Giant of Cancer Care in Genitourinary Cancers, discusses the phase II EV-201 trial of enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer who were previously treated with platinum-based chemotherapy or a PD-1/PD-L1 checkpoint inhibitor.

Patients with non–small cell lung cancer and baseline liver metastases had improved progression-free survival and overall survival with the addition of immunotherapy to bevacizumab and a chemotherapy doublet.

Two highly selective MET inhibitors, tepotinib and capmatinib showed promising clinical activity in the first- and second-line treatment of patients with MET exon 14-altered advanced non–small cell lung cancer.

Adding ramucirumab to erlotinib reduced the risk of disease progression or death by over 40% versus erlotinib alone as a frontline treatment for patients with EGFR-positive NSCLC.

The FDA has unveiled what it describes as a pilot “concierge service” for oncologists and patients seeking information and assistance with expanded access to investigational therapies.

Neoadjuvant immunotherapy demonstrated substantial activity with a favorable toxicity profile in findings from 2 studies of patients with operable early-stage non–small cell lung cancer reported at the 2019 ASCO Annual Meeting.

More than 70% of female gynecologic oncologists in the United States and more than half of male practitioners have experienced sexual harassment in training or practice, according to results from a survey conducted by the Society of Gynecologic Oncology.

Similar long-term rates of survival were seen in patients with colorectal cancer and liver metastases regardless of whether the patient underwent laparoscopic or open liver surgery.

A broader set of clinical trial eligibility criteria proposed by the American Society of Clinical Oncology and Friends of Cancer Research would nearly double the number of patients with advanced non-small cell lung cancer available for enrollment.

Enfortumab vedotin induced responses in 44% of patients with locally advanced or metastatic urothelial cancer, including 12% experiencing a complete response to treatment.

Talia Golan, MD, head of Sheba Pancreatic Cancer Center, discusses the results of the phase III POLO trial, which evaluated maintenance olaparib compared with placebo among patients with germline BRCA-mutated metastatic pancreatic cancer.

Christopher Sweeney, MBBS, medical oncologist at the Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, discusses results of the phase III ENZAMET trial, which looked at standard therapy with or without enzalutamide as a treatment for patients with metastatic hormone-sensitive prostate cancer.

Adding isatuximab to pomalidomide and low-dose dexamethasone led to a greater than 40% reduction in the risk of disease progression or death compared with pomalidomide and dexamethasone alone in patients with relapsed/refractory multiple myeloma.

A subcutaneous flat-dose version of daratumumab demonstrated noninferior efficacy with a reduction in the treatment burden compared with the original intravenous formulation of the anti-CD38 monoclonal antibody for patients with relapsed/refractory multiple myeloma.